We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

81 hedge funds and large institutions have $893M invested in Pliant Therapeutics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

7% more funds holding

Funds holding: 76 → 81 (+5)

0.44% less ownership

Funds ownership: 85.95% → 85.51% (-0.44%)

26% less capital invested

Capital invested by funds: $1.21B → $893M (-$314M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $189K

Holders
81
Holders Change
+5
Holders Change %
+6.58%
% of All Funds
1.41%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
12
Increased
27
Reduced
23
Closed
7
Calls
–
Puts
$189K
Net Calls
-$189K
Net Calls Change
-$189K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$5.26M
2
FIM
Fernwood Investment Management
Massachusetts
+$4.7M
3
BDFN
Bond & Devick Financial Network
Minnesota
+$3.74M
4
WP
Woodline Partners
California
+$2.23M
5
SFM
Sphera Funds Management
Israel
+$1.59M

Top Sellers

1
FCM
Farallon Capital Management
California
-$8.54M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.02M
3
BlackRock
BlackRock
New York
-$3.65M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$3.63M
5
RG
Redmile Group
California
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
$277K – – –
Invesco
52
Invesco
Georgia
$276K +$296K +9,503 New
Bank of America
53
Bank of America
North Carolina
$251K +$55K +1,768 +26%
CS
54
Credit Suisse
Switzerland
$216K -$22.7K -728 -9%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$213K +$11.3K +362 +5%
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$203K -$580K -18,639 -73%
VEA
57
Virtus ETF Advisers
New York
$198K -$129K -4,151 -38%
Citigroup
58
Citigroup
New York
$123K +$35.6K +1,143 +37%
Legal & General Group
59
Legal & General Group
United Kingdom
$96K -$529 -17 -0.5%
GWM
60
Geneos Wealth Management
Colorado
$87K – – –
SO
61
STRS Ohio
Ohio
$87K +$12.5K +400 +15%
AIP
62
Ameritas Investment Partners
Nebraska
$57K – – –
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$48K -$15K -481 -23%
TRCT
64
Tower Research Capital (TRC)
New York
$46K +$1.06K +34 +2%
UBS Group
65
UBS Group
Switzerland
$41K +$15.6K +501 +56%
SOW
66
State of Wyoming
Wyoming
$29K +$17.8K +572 +140%
PCM
67
Penserra Capital Management
California
$23K +$467 +15 +2%
Canada Life
68
Canada Life
Manitoba, Canada
$19K – – –
PA
69
Parallel Advisors
California
$19K +$20.5K +658 New
US Bancorp
70
US Bancorp
Minnesota
$17K – – –
HI
71
Harbour Investments
Wisconsin
$10K +$62 +2 +0.6%
First Manhattan
72
First Manhattan
New York
$5K – – –
LWANC
73
Laurel Wealth Advisors (North Carolina)
North Carolina
$5K +$4.98K +160 New
Osaic Holdings
74
Osaic Holdings
Arizona
$4K -$4.67K -150 -50%
Daiwa Securities Group
75
Daiwa Securities Group
Japan
$2K – – –
1 2
3
4

PLRX Hedge Fund Activity: Q2 2021 in Review

81 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2021, worth a combined $893M — down 26% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PLRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 23 trimmed.

The largest buyer was Vanguard Group, adding an estimated $5.26M. The largest seller was Farallon Capital Management, cutting an estimated $8.54M.

  • 81 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2021, up from 76 in Q1 2021.
  • Funds reported $893M of Pliant Therapeutics stock for Q2 2021, down 26% quarter-over-quarter.
  • 12 funds opened new Pliant Therapeutics positions in Q2 2021 and 7 closed out, a net change of +5 holders.
  • The largest Pliant Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $5.26M added.
  • The largest Pliant Therapeutics seller in Q2 2021 was Farallon Capital Management, an estimated $8.54M sold.

Based on aggregated 13F filings for Q2 2021.